|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
1999-12-2
|
|
pubmed:abstractText |
Tamoxifen is currently the first-line therapy for treatment of hormone-dependent breast cancer. However, despite initial benefits, most patients eventually relapse. Two groups of patients were identified: (a) a tamoxifen-sensitive group (n = 8); and (b) a tamoxifen-resistant group (n = 9). Using reverse transcription-PCR, the relative expression of mRNA for both estrogen receptor (ER) beta and transforming growth factor beta1 was determined in each patient group and quantified against a known reference standard. ER-beta mRNA was significantly up-regulated in the tamoxifen-resistant group as compared with the tamoxifen-sensitive group (P = 0.001 by Fisher's exact test), and, consistent with previous findings, transforming growth factor beta1 was also up-regulated in the tamoxifen-resistant cohort (P = 0.02). The importance of ER-beta in tamoxifen resistance was validated using tamoxifen-sensitive and -resistant cell lines, in which it was demonstrated that ER-beta mRNA was significantly up-regulated in the resistant cells. These results lend further support to a role for ER-beta as a poor prognostic factor in breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor beta,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-5472
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5421-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10554009-Aged,
pubmed-meshheading:10554009-Antineoplastic Agents, Hormonal,
pubmed-meshheading:10554009-Breast Neoplasms,
pubmed-meshheading:10554009-Case-Control Studies,
pubmed-meshheading:10554009-DNA, Complementary,
pubmed-meshheading:10554009-Drug Resistance, Neoplasm,
pubmed-meshheading:10554009-Estrogen Receptor beta,
pubmed-meshheading:10554009-Female,
pubmed-meshheading:10554009-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:10554009-Humans,
pubmed-meshheading:10554009-Male,
pubmed-meshheading:10554009-Middle Aged,
pubmed-meshheading:10554009-RNA, Messenger,
pubmed-meshheading:10554009-Receptors, Estrogen,
pubmed-meshheading:10554009-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:10554009-Tamoxifen,
pubmed-meshheading:10554009-Testis,
pubmed-meshheading:10554009-Transforming Growth Factor beta,
pubmed-meshheading:10554009-Tumor Cells, Cultured
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
|
|
pubmed:affiliation |
Department of Medicine, University of Hull, England, United Kingdom. v.speirs@leeds.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
